Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
5-fluorouracil (5-FU) poisoning is a rare intoxication caused by the prolonged, low-dose administration of 5-FU, which is the mainstay of both adjuvant and advanced-disease chemotherapy regimens in colon cancer. 5-FU poisoning is characterized by gastrointestinal (nausea, emesis, diarrhea, anorexia, stomatitis) and hematologic (myelosuppression) toxicities as well as mucositis, alopecia and, occasionally, palmar-plantar dysesthesia (more commonly known as hand-foot syndrome). Women have been reported to experience more 5-FU-related toxicity than men.
Biomarker and diagnostic research for 5-fluorouracil poisoning has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
No clinical trials have been registered for 5-fluorouracil poisoning.
27 publications have been identified in PubMed for 5-fluorouracil poisoning. Research spans Basic Science / Preclinical (63%), Case Report / Case Series (11%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 17 | 63% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:53 PM UTC
European rare disease database
Common questions about 5-fluorouracil poisoning
3 |
11% |
Disease patterns and progression | 3 | 11% |
Research summaries | 2 | 7% |
Testing and diagnosis research | 1 | 4% |
Clinical study results | 1 | 4% |
Abd El-Fattah W (2026). [PMID: 42123474](https://pubmed.ncbi.nlm.nih.gov/42123474/). *Int J Mol Sci*. [Basic Science / Preclinical]
Hansen SH (2026). [PMID: 41240351](https://pubmed.ncbi.nlm.nih.gov/41240351/). *Clinical chemistry and laboratory medicine*. [Basic Science / Preclinical]
Thetchana Priya M (2026). [PMID: 41687884](https://pubmed.ncbi.nlm.nih.gov/41687884/). *Toxicology and applied pharmacology*. [Basic Science / Preclinical]
Wang Y (2026). [PMID: 41766865](https://pubmed.ncbi.nlm.nih.gov/41766865/). *Frontiers in immunology*. [Case Report / Case Series]
Okechukwu CC (2025). [PMID: 40940837](https://pubmed.ncbi.nlm.nih.gov/40940837/). *Cancers*. [Basic Science / Preclinical]
Eissa MA (2025). [PMID: 39369924](https://pubmed.ncbi.nlm.nih.gov/39369924/). *Journal of ethnopharmacology*. [Basic Science / Preclinical]
Alharbi AM (2025). [PMID: 40228806](https://pubmed.ncbi.nlm.nih.gov/40228806/). *Human & experimental toxicology*. [Basic Science / Preclinical]
Assenat E (2025). [PMID: 40540704](https://pubmed.ncbi.nlm.nih.gov/40540704/). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. [Clinical Trial Publication]
Warrad R (2025). [PMID: 40394524](https://pubmed.ncbi.nlm.nih.gov/40394524/). *BMC cancer*. [Epidemiology / Natural History]
Al-Abbas NS (2025). [PMID: 40852754](https://pubmed.ncbi.nlm.nih.gov/40852754/). *Human & experimental toxicology*. [Basic Science / Preclinical]
AI-curated news mentioning 5-fluorouracil poisoning
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.